Cargando…

Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report

INTRODUCTION: Olfactory reference syndrome (ORS) (halitophobia) is the excessive fear of having bad breath without clinical findings supporting the patient's complaints. In this case report, a low dose of aripiprazole (ARP) successfully improved oral cenesthopathy and then improved ORS. CASE PR...

Descripción completa

Detalles Bibliográficos
Autores principales: Takenoshita, Miho, Motomura, Haruhiko, Toyofuku, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594496/
https://www.ncbi.nlm.nih.gov/pubmed/34538856
http://dx.doi.org/10.1097/WNF.0000000000000476
_version_ 1784600004676026368
author Takenoshita, Miho
Motomura, Haruhiko
Toyofuku, Akira
author_facet Takenoshita, Miho
Motomura, Haruhiko
Toyofuku, Akira
author_sort Takenoshita, Miho
collection PubMed
description INTRODUCTION: Olfactory reference syndrome (ORS) (halitophobia) is the excessive fear of having bad breath without clinical findings supporting the patient's complaints. In this case report, a low dose of aripiprazole (ARP) successfully improved oral cenesthopathy and then improved ORS. CASE PRESENTATION: A 44-year-old female patient complained of a sensation of astringent film sticking on her tongue. She was also very anxious about her bad breath at work. We prescribed 0.5 mg of ARP for her symptoms because she worried about potential drowsiness. One week later, the patient reported that the oral sensation had resolved 2 to 3 days after the mediation was administered. No obvious adverse effects were observed except temporary arousal during sleep. Three months after the initial visit, her symptoms worsened, partly because of her job change, so we increased the dose of ARP from 0.5 mg to 1 mg. Later, the patient reported that she was better able to manage the anxiety about her breath. At the 2-year follow-up, her symptoms have continued to improve without medication. CONCLUSIONS: Although the most effective approach to ORS is not established, the current study indicates that a low dose of ARP to treat oral cenesthopathy might improve ORS.
format Online
Article
Text
id pubmed-8594496
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85944962021-11-19 Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report Takenoshita, Miho Motomura, Haruhiko Toyofuku, Akira Clin Neuropharmacol Case Reports INTRODUCTION: Olfactory reference syndrome (ORS) (halitophobia) is the excessive fear of having bad breath without clinical findings supporting the patient's complaints. In this case report, a low dose of aripiprazole (ARP) successfully improved oral cenesthopathy and then improved ORS. CASE PRESENTATION: A 44-year-old female patient complained of a sensation of astringent film sticking on her tongue. She was also very anxious about her bad breath at work. We prescribed 0.5 mg of ARP for her symptoms because she worried about potential drowsiness. One week later, the patient reported that the oral sensation had resolved 2 to 3 days after the mediation was administered. No obvious adverse effects were observed except temporary arousal during sleep. Three months after the initial visit, her symptoms worsened, partly because of her job change, so we increased the dose of ARP from 0.5 mg to 1 mg. Later, the patient reported that she was better able to manage the anxiety about her breath. At the 2-year follow-up, her symptoms have continued to improve without medication. CONCLUSIONS: Although the most effective approach to ORS is not established, the current study indicates that a low dose of ARP to treat oral cenesthopathy might improve ORS. Lippincott Williams & Wilkins 2021 2021-09-20 /pmc/articles/PMC8594496/ /pubmed/34538856 http://dx.doi.org/10.1097/WNF.0000000000000476 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Reports
Takenoshita, Miho
Motomura, Haruhiko
Toyofuku, Akira
Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report
title Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report
title_full Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report
title_fullStr Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report
title_full_unstemmed Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report
title_short Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report
title_sort olfactory reference syndrome (halitophobia) with oral cenesthopathy treated with low-dose aripiprazole: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594496/
https://www.ncbi.nlm.nih.gov/pubmed/34538856
http://dx.doi.org/10.1097/WNF.0000000000000476
work_keys_str_mv AT takenoshitamiho olfactoryreferencesyndromehalitophobiawithoralcenesthopathytreatedwithlowdosearipiprazoleacasereport
AT motomuraharuhiko olfactoryreferencesyndromehalitophobiawithoralcenesthopathytreatedwithlowdosearipiprazoleacasereport
AT toyofukuakira olfactoryreferencesyndromehalitophobiawithoralcenesthopathytreatedwithlowdosearipiprazoleacasereport